Research Insight
Capravirine – Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is a Non-Nuclesoide Reverse Transcriptase Inhibitor (NNRTI) that was under development for the treatment of patients infected with the Human Immunodeficiency Virus (HIV). It was indicated for patients with HIV/AIDS who...
Research Insight
Abraxane for the Treatment of Late-Stage Pancreatic Cancer, United States of America
Abraxane (albumin-bound paclitaxel for injectable suspension) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer. The drug was originally developed by Abraxis BioScience, which was acquired by Celgene Corporation in October 2010. Celgene...
Research Insight
Cetilistat – Investigational Drug for Obesity, Japan
Developed by Alizyme, a specialist biopharmaceutical company in collaboration with Takeda Pharmaceutical, cetilistat (ATL-962) is an experimental treatment for obesity. Cetilistat restricts pancreatic lipases and acts as an agent to treat obesity and related diabetes or dyslipidemia. ...
Research Insight
Drug to fight leukemia in sight, say Australian researchers
After discovering a potential molecular "target" for leukemia, Australian researchers say a drug to fight the disease is "in their sights," although it is still very early days. Writing in the journal Blood, they describe how the interaction of...
Research Insight
Zonegran (Zonisamide) for the Treatment of Epilepsy, Switzerland
Zonegran (Zonisamide) is an anti-epileptic drug indicated for the treatment of partial seizures in adults with epilepsy with or without secondary generalisation. The drug was originally discovered and developed by Dainippon Pharmaceutical (now Dainippon Sumitomo Pharma)....
Research Insight
Pharma 2020
A recent study by PricewaterhouseCoopers (PwC) examined the future of pharma and revealed essential technological and IT strategies. Developments in manufacturing, research and development (R&D), and IT will shape the future of pharma, as Ingrid Maes of PwC elaborates....
Research Insight
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes, India
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics. The drug was discovered and developed by Zydus Cadila, a pharmaceutical company based in India. Zydus...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read